早期结直肠癌非治愈性内镜黏膜下剥离术的临床结局
这项回顾性多中心分析纳入13个中心至2019年连续接受内镜黏膜下剥离术的T1期结直肠癌患者3373例,其中207例(34.3%)为非治愈性切除;126例接受手术,81例仅随访。随访组总体死亡率更高(HR=3.95),死因为非结直肠癌;两组肿瘤复发率和疾病特异性生存率无差异(中位随访30个月)。
要点
- T1期结直肠癌非治愈性内镜黏膜下剥离术后,仅随访组总体死亡率高于手术组(HR=3.95),死因为非结直肠癌。
- 两组肿瘤复发率和疾病特异性生存率无差异,中位随访30个月。
- 手术组残留病率为19.8%(25/126),随访组81例均接受内镜随访。
核心结论
- 对残留病高风险病灶行内镜黏膜下剥离术后,手术高风险患者仅随访可能是合理选择(作者结论),同时应提高内镜切除质量。
研究设计与样本
- 回顾性分析13个中心至2019年连续接受内镜黏膜下剥离术的T1期结直肠癌患者3373例,纳入非治愈性切除且随访数据可得的207例(男138例,平均年龄67.6±10.9岁)。
- 非治愈性切除定义为G3、黏膜下浸润>1000 µm、淋巴血管侵犯、出芽或切除不全/R1;合并症按Charlson合并症指数(CCI)分类。
- 结局为两组疾病复发率、死亡率和疾病相关死亡率;手术组评估原切除部位和区域淋巴结的残留病,随访组通过随访评估。
- 试验注册号NCT03987828。
主要发现
- 207例非治愈性切除中,65.2%未达到完整切除(R1)。
- 126例(60.9%,中位CCI 3,IQR 2-4)接受手术治疗,残留病率19.8%(25/126)。
- 81例(39.1%,中位CCI 5,IQR 4-6)仅接受内镜随访。
- 随访组总体死亡率更高(HR=3.95),死因为非结直肠癌(n=9,内镜黏膜下剥离术后平均生存23.7±13.7个月)。
- 中位随访30个月(范围6-105),两组肿瘤复发率和疾病特异性生存率无差异。
关键数值与推荐
- 非治愈性切除标准:G3、黏膜下浸润>1000 µm、淋巴血管侵犯、出芽或切除不全/R1。
- 合并症按Charlson合并症指数(CCI)分类,手术组中位CCI 3(IQR 2-4),随访组中位CCI 5(IQR 4-6)。
- 残留病率在手术组为19.8%(25/126)。
临床怎么用
- 作者认为,对残留病高风险病灶行内镜黏膜下剥离术后,手术高风险患者仅随访可能是合理选择。
- 作者认为,应提高内镜切除质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endoscopic submucosal dissection (ESD) in a curative intent for submucosa-invasive early (T1) colorectal cancers (T1-CRCs) often leads to subsequent surgical resection in case of histologic parameters indicating higher risk of nodal involvement. In some cases, however, the expected benefit may be offset by the surgical risks, suggesting a more conservative approach. DESIGN: Retrospective analysis of consecutive patients with T1-CRC who underwent ESD at 13 centres ending inclusion in 2019 (n=3373). Cases with high risk of nodal involvement (non-curative ESD: G3, submucosal invasion>1000 µm, lymphovascular involvement, budding or incomplete resection/R1) were analysed if follow-up data (endoscopy/imaging) were available, regardless of the postendoscopic management (follow-up vs surgery) selected by the multidisciplinary teams in these institutions. Comorbidities were classified according to Charlson Comorbidity Index (CCI). Outcomes were disease recurrence, death and disease-related death rates in the two groups. Rate of residual disease (RD) at both the previous resection site and regional lymph nodes was assessed in the surgical cases as well as from follow-up in the follow-up group. RESULTS: Of 604 patients treated by colorectal ESD for submucosally invasive cancer, 207 non-curative resections (34.3%) were included (138 male; mean age 67.6±10.9 years); in 65.2% of cases, no complete resection was achieved (R1). Of the 207 cases, 60.9% (n=126; median CCI: 3; IQR: 2-4) underwent surgical treatment with RD in 19.8% (25/126), while 39.1% (n=81, median CCI: 5; IQR: 4-6) were followed up by endoscopy in all cases. Patients in the follow-up group had a higher overall mortality (HR=3.95) due to non-CRC causes (n=9, mean survival after ESD 23.7±13.7 months). During this follow-up time, tumour recurrence and disease-specific survival rates were not different between the groups (median follow-up 30 months; range: 6-105). CONCLUSION: Following ESD for a lesion at high risk of RD, follow-up only may be a reasonable choice in patients at high risk for surgery. Also, endoscopic resection quality should be improved. TRIAL REGISTRATION NUMBER: NCT03987828.
引用
- Spadaccini M, Bourke MJ, Maselli R, et al. Clinical outcome of non-curative endoscopic submucosal dissection for early colorectal cancer. Gut. 2022. PMID: 35058275. doi:10.1136/gutjnl-2020-323897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。